---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-023503"
form_type: "8-K"
ticker: "TCRX"
cik: "0001783328"
company_name: "TScan Therapeutics, Inc."
filed_at: "2022-11-09T23:59:59+00:00"
generated_at: "2026-06-22T01:45:32.600481+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# TScan Therapeutics reports Q3 net loss of $16.2M and cash of $137.3M

## Summary
- Net loss $16.2M vs $15.8M YoY; revenue $3.4M vs $2.4M YoY.
- Cash and equivalents $137.3M; closed $60M debt facility with K2 HealthVentures, initial $30M drawn.
- Phase 1 umbrella trial for TSC-100/101 enrolling; pre-IND meeting with FDA completed for solid tumors.
- Plan IND submissions for MAGE-A1 TCRs by end 2022; HPV and PRAME INDs by H1 2023.
- Virtual investor event Nov 14, 2022 to detail solid tumor clinical development plans.

## SEC filing metadata
- accession: 0000950170-22-023503
- form_type: 8-K
- ticker: TCRX
- cik: 0001783328
- company_name: TScan Therapeutics, Inc.
- filed_at: 2022-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783328/000095017022023503/0000950170-22-023503-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783328/000095017022023503/tcrx-20221109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-023503
- JSON: https://secwatch.observer/filing/0000950170-22-023503.json
- Plain text: https://secwatch.observer/filing/0000950170-22-023503.txt

## Key facts
- Earnings Releases
  TScan Therapeutics, Inc. reported the third quarter ended September 30, 2022 results: revenue $3.4 million.
  - Period: the third quarter ended September 30, 2022
  - Revenue: $3.4 million
  - Result: reported results
  source text: be sufficient to fund its operating expenses and capital expenditure requirements into the second quarter of 2024. Revenue for the third quarter ended September 30, 2022, was $3.4 million, compared to $2.4 million for the third quarter ended September 30, 2021 (2021 Quarter). This increase is due to research activities related to TScan’s collaboration agreement
  evidence_url: https://www.sec.gov/Archives/edgar/data/1783328/000095017022023503/0000950170-22-023503-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.